 |
|
|
Alexander Glassman, M.D.
Professor of Clinical Psychiatry
Chief: Clinical Psychopharmacology,
New York State Psychiatric Institute
|
|
|
|
|
|
|
|
|
Alexander H. Glassman, M.D., is Chief of Clinical Psychopharmacology at New York State Psychiatric Institute, and Professor of Psychiatry at the College of Physicians and Surgeons of Columbia University. He is an authority on depression and antidepressant drugs, and has altered the standard of care for depressed patients.
He showed that inter-individual differences in metabolism of imipramine influenced clinical outcome and that delusional unipolar depression responded very poorly to antidepressant drugs alone. His work has clarified the safe treatment of depressed patients with cardiovascular disease. He has demonstrated a strong association between major depression and cigarette smoking and has shown that this history of major depression greatly reduces the chances that a smoker will successfully stop and that if such a smoker should successfully stop, he is at significant risk to develop serious depression.
He has more recently been involved in studies of the relationship between depression and cardiovascular mortality.
Dr. Glassman was the recipient of the American Psychiatric Association's Foundation Fund Prize for lifetime accomplishment in Research, the Established Investigator's Award of the National Association for Research in Schizophrenia and Affective Disorders, the New York State Research Award and the 2007-2008 Anna-Monika Foundation Prize for reseach in depression.
He is the author of over 300 scientific publications and serves on the editorial boards of Heart Disease and the Journal of Clinical Psychopharmacology. His many professional affiliations include membership in the American Association for the Advancement of Science, the Council of Research Scientists, the International Congress of Neuropsychopharmacology, and others. He is a fellow of the American College of Neuropsychopharmacology, a life fellow of the American Psychiatric Association, a member of the scientific advisory board of the National Alliance for Research on Schizophrenia and Depression (NARSAD), and a member of the scientific advisory panel of the American Legacy Panel. His major research interests are affective disorders, psychopharmacology, and smoking cessation.
|
 |
Undergraduate: University of Illinois, B.S., 1951-1954
Medical School: University of IL. College of Medicine, M.D., 1954-1958
Internship: D.C. General Hospital, 1958 - 1959
Residency: Jacobi Hospital, Psychiatry, 1959 - 1962
Board Certifications: American Board of Psychiatry & Neurology
|
 |
• Depression
|
 |
Address:
NYS Psychiatric Institute
Room 2726 Unit/Box:116
1051 Riverside Drive
New York, NY 10032
Phone: 212 543-5750
Fax: 212 543-6100
ahg1@columbia.edu
|
 |
| The relationship between depression and cardiovascular disease.
|
 |
1. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT et al.: SertralineTreatment of Major Depression in Patients with Acute MI or Unstable Angina. . JAMA 2002;288(6):: 701-709
2. Glassman AH, Bigger JT: Antidepressants in coronary heart disease: SSRIs reduce depression, but do they save lives?. JAMA 2007;297(4):: 411-412
3. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, Petkova E, Rodriguez K.: A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. . Addiction 2007;102(8):: 1293-1302
4. Glassman AH: Cigarette smoking: Implications for psychiatric illness. Special Article
. Amer J Psychiat 1993;150: 546-553
5. Glassman AH, Bigger JT.: Antipsychotic drugs: prolonged QTc, torsade de pointes, and sudden
Death
. Am J Psychiatry 2001;158(11):: 1774-1782
|
 |
|
FACULTY ONLY
|
|
|
